CRSP vs DGX · rev $11.6M vs P/E 22, rev $5.94B
Crispr Therapeutics AG (CRSP) versus Quest Diagnostics Incorporated (DGX) — a side-by-side from cached financials, not a winner call.
Crispr Therapeutics AG (CRSP) is a biotechnology company listed on US.
Quest Diagnostics Incorporated (DGX) is a diagnostics & research company listed on US.
Latest reported CRSP revenue for 2026-06-30 was $11.6M. Net income was -$214.1M. CRSP currently screens at market cap $5.42B.
Latest reported DGX revenue for 2026-06-30 was $5.94B. Net income was $572.0M. DGX currently screens at market cap $19.94B and trailing P/E 22.4.
CRSP currently screens at market cap $5.42B. DGX currently screens at market cap $19.94B and trailing P/E 22.4.
Not investment advice. Open the CRSP and DGX stock pages for the full models.
Not investment advice.